Asunto(s)
Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa , Humanos , Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/diagnóstico , Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/genética , Tiamina/uso terapéutico , Debilidad Muscular/genética , MutaciónRESUMEN
BACKGROUND: Carnitine palmitoyltransferase (CPT) II deficiency is one of the most common forms of mitochondrial fatty acid oxidation disorder (FAOD). However, newborn screening (NBS) for this potentially fatal disease has not been established partly because reliable indices are not available. METHODS: We diagnosed CPT II deficiency in a 7-month-old boy presenting with hypoglycemic encephalopathy, which apparently had been missed in the NBS using C16 and C18:1 concentrations as indices. By referring to his acylcarnitine profile from the NBS, we adopted the (C16+C18:1)/C2 ratio (cutoff 0.62) and C16 concentration (cutoff 3.0nmol/mL) as alternative indices for CPT II deficiency such that an analysis of a dried blood specimen collected at postnatal day five retroactively yielded the correct diagnosis. Thereafter, positive cases were assessed by measuring (1) the fatty acid oxidation ability of intact lymphocytes and/or (2) CPT II activity in the lysates of lymphocytes. The diagnoses were then further confirmed by genetic analysis. RESULTS: The disease was diagnosed in seven of 21 newborns suspected of having CPT II deficiency based on NBS. We also analyzed the false-negative patient and five symptomatic patients for comparison. Values for the NBS indices of the false-negative, symptomatic patient were lower than those of the seven affected newborns. Although it was difficult to differentiate the false-negative patient from heterozygous carriers and false-positive subjects, the fatty acid oxidation ability of the lymphocytes and CPT II activity clearly confirmed the diagnosis. Among several other indices proposed previously, C14/C3 completely differentiated the seven NBS-positive patients and the false-negative patient from the heterozygous carriers and the false-positive subjects. Genetic analysis revealed 16 kinds of variant alleles. The most prevalent, detected in ten alleles in nine patients from eight families, was c.1148T>A (p.F383Y), a finding in line with those of several previous reports on Japanese patients. CONCLUSIONS: These findings suggested that CPT II deficiency can be screened by using (C16+C18:1)/C2 and C16 as indices. An appropriate cutoff level is required to achieve adequate sensitivity albeit at the cost of a considerable increase in the false-positive rate, which might be reduced by using additional indices such as C14/C3.
Asunto(s)
Carnitina O-Palmitoiltransferasa/análisis , Carnitina O-Palmitoiltransferasa/deficiencia , Errores Innatos del Metabolismo/diagnóstico , Tamizaje Neonatal , Palmitoilcarnitina/análisis , Alelos , Carnitina O-Palmitoiltransferasa/genética , Pruebas con Sangre Seca/métodos , Reacciones Falso Negativas , Reacciones Falso Positivas , Femenino , Humanos , Hipoglucemia/complicaciones , Lactante , Recién Nacido , Masculino , Errores Innatos del Metabolismo/genética , Sensibilidad y Especificidad , Espectrometría de Masas en TándemRESUMEN
We report a 21-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA) showing progressive myoclonus epilepsy (PME), who responded to levetiracetam (LEV) at an initial dose of 1,000 mg/day. The patient developed epilepsy at the age of 10 years, and also showed intellectual regression. Various antiepileptic drugs showed no effects on generalized tonic seizures, tonic-clonic seizures, and myoclonus. Addition of LEV (1,000 mg/day) led to the reduction of myoclonus and tonic-clonic seizures, and improved the EEG and sleep-wake rhythm. He had a better appetite and gain weight. It is suggested that LEV may improve quality of life in patients with DRPLA, in addition to reducing the frequency of epileptic seizures.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Ritmo Circadiano/efectos de los fármacos , Epilepsias Mioclónicas Progresivas/tratamiento farmacológico , Piracetam/análogos & derivados , Anticonvulsivantes/efectos adversos , Electroencefalografía/efectos de los fármacos , Humanos , Levetiracetam , Masculino , Epilepsias Mioclónicas Progresivas/complicaciones , Epilepsias Mioclónicas Progresivas/etiología , Piracetam/efectos adversos , Piracetam/uso terapéutico , Adulto JovenRESUMEN
BACKGROUND: Pyruvate dehydrogenase complex (PDHC) deficiency is an inborn error of metabolism that causes lactic acidosis and neurodevelopmental changes. Five causative genes have been identified: PDHA1, PDHB, DLAT, DLD, and PDHX. Four neurological phenotypes have been reported: neonatal encephalopathy with lactic acidosis, non-progressive infantile encephalopathy, Leigh syndrome, and relapsing ataxia. Of these, neonatal encephalopathy has the worst mortality and morbidity and there is no effective treatment. SUBJECTS AND METHODS: We studied two girls who were clinically diagnosed with PDHC deficiency as neonates; they were subsequently found to have PDHA1 mutations. The clinical diagnosis was based on white matter loss and a lateral ventricular septum on fetal MRI, spasticity of the lower extremities, and lactic acidosis worsening after birth. Intravenous ketogenic diets were started within 24 h after birth. The ketogenic ratio was increased until the blood lactate level was controlled, while monitoring for side effects. RESULTS: In both cases, the lactic acidosis improved immediately with no apparent side effects. Both children had better developmental outcomes than previously reported cases; neither exhibited epilepsy. CONCLUSIONS: Intravenous ketogenic diet therapy is a treatment option for neonatal-onset PDHC deficiency. Further studies are needed to optimize this therapy.
Asunto(s)
Dieta Cetogénica , Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/dietoterapia , Femenino , Humanos , Lactante , Recién Nacido , Nutrición ParenteralRESUMEN
The introduction of tandem mass spectrometry (MS/MS) has made it possible to screen for very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. To confirm the diagnosis in cases with an abnormal profile of blood acylcarnitines, we developed a new enzymatic assay method for determining dehydrogenase activity toward palmitoyl-CoA (C16:0) in lymphocytes. Using this method, the production of 2-hexadecenoyl-CoA (C16:1) by crude cell lysates can be directly quantified using high performance liquid chromatography (HPLC). We applied the assay to 7 myopathic patients, 7 hypoglycemic patients, and 2 presymptomatic newborns with elevated levels of tetradecenoylcarnitine (C14:1 AC) in blood, and found impaired VLCAD activity in all of the 7 myopathic patients and both of the 2 newborns. All of the 7 hypoglycemic patients had normal level of the enzyme activity. Results of the ACADVL gene analysis were in consistent with the enzymatic diagnosis. These results suggest that MS/MS-based screening for VLCAD deficiency using blood C14:1 AC as the indicator may show a considerably high false-positive rate in selective screening of symptomatic patients. Our practical enzymatic assay can be a useful test for the accurate diagnosis of VLCAD deficiency cases screened by MS/MS.
Asunto(s)
Acilcoenzima A/metabolismo , Acil-CoA Deshidrogenasa de Cadena Larga/deficiencia , Trastornos del Metabolismo de los Lípidos/diagnóstico , Tamizaje Neonatal/métodos , Espectrometría de Masas en Tándem/métodos , Acil-CoA Deshidrogenasa de Cadena Larga/genética , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Recién Nacido , Japón , Trastornos del Metabolismo de los Lípidos/genética , Masculino , Palmitoil Coenzima A/metabolismo , Adulto JovenRESUMEN
We report 2 patients of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and consider the pathophysiology of stroke-like lesions, using magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI) on MRI, perfusion imaging on MRI, and 1H magnetic resonance spectroscopy (1H-MRS). In Patient 1, T2-weighted imaging (T2-WI) on MRI at onset and even at 44 days after onset of the stroke-like episode showed high intensity in left parietal, temporal, and occipital lobe lesions. In the temporal lobe lesion, the apparent diffusion coefficient (ADC) at 44 days after onset was higher (average: 1.219x10(-3)mm2/s) than that in a normal region (average: 0.796x10(-3)mm2/s). (1)H-MRS of the left parietal lobe lesion at the same day showed a decrease in N-acetylaspartate/(creatine+phosphocreatine) (NAA/Cr) (0.43) and a peak in lactate. 1H-MRS of the contralateral side at the same day showed NAA/Cr (1.57) and no peak in lactate. Thereafter, ADC gradually decreased and NAA/Cr gradually increased, and the peak in lactate disappeared in the lesion. In Patient 2, T2-WI at onset showed high intensity in bilateral occipital lobe lesions. In the left occipital lobe lesion, ADC at the same day was higher (1.082x10(-3)mm2/s) than that in a normal region (average: 0.841x10(-3)mm2/s). (1)H-MRS of the left occipital lobe lesion at the same day showed a decrease of NAA (3.0mM) and a peak in lactate (13.1mM) (measured by LCModel). In 1H-MRS of the normal left parietooccipital lobe at 4 months before onset, NAA was 7.6mM and there was no peak in lactate (0mM). Perfusion imaging at onset showed high intensity in bilateral occipital lobes, which indicated hyperperfusion in stroke-like lesions. Thereafter, ADC gradually decreased and the peak in lactate partially decreased, and the low concentration of NAA persisted (regardless of the partial recovery) in the lesion. These results suggest that the stroke-like episodes is related to vasogenic edema, hyperperfusion, and neuronal damage. Acute oxidative phosphorylation defect may have a crucial role in the pathophysiology of stroke-like episodes.
Asunto(s)
Encéfalo/patología , Diagnóstico por Imagen/métodos , Síndrome MELAS/diagnóstico , Encéfalo/fisiopatología , Niño , Preescolar , Imagen de Difusión por Resonancia Magnética/métodos , Humanos , Síndrome MELAS/fisiopatología , Angiografía por Resonancia Magnética/métodos , Imagen por Resonancia Magnética/métodos , Espectroscopía de Resonancia Magnética/métodos , MasculinoRESUMEN
The human pyruvate dehydrogenase complex (PDHC) catalyzes the thiamine-dependent decarboxylation of pyruvate. Thiamine treatment is very effective for some patients with PDHC deficiency. Among these patients, five mutations of the pyruvate dehydrogenase (E1)alpha subunit have been reported previously: H44R, R88S, G89S, R263G, and V389fs. All five mutations are in a region outside the thiamine pyrophosphate (TPP)-binding region of the E1alpha subunit. We report the biochemical and molecular analysis of two patients with clinically thiamine-responsive lactic acidemia. The PDHC activity was assayed using two different concentrations of TPP. These two patients displayed very low PDHC activity in the presence of a low (1 x 10(-4) mM) TPP concentration, but their PDHC activity significantly increased at a high (0.4 mM) TPP concentration. Therefore, the PDHC deficiency in these two patients was due to a decreased affinity of PDHC for TPP. Treatment of both patients with thiamine resulted in a reduction in the serum lactate concentration and clinical improvement, suggesting that these two patients have a thiamine-responsive PDHC deficiency. The DNA sequence of these two male patients' X-linked E1alpha subunit revealed a point mutation (F205L and L216F) within the TPP-binding region in exon 7.
Asunto(s)
Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/tratamiento farmacológico , Complejo Piruvato Deshidrogenasa/genética , Tiamina/uso terapéutico , Sitios de Unión , Células Cultivadas , Niño , Exones , Humanos , Lactante , Ácido Láctico/sangre , Linfocitos/efectos de los fármacos , Linfocitos/enzimología , Masculino , Mutación Puntual , Piruvato Descarboxilasa/metabolismo , Complejo Piruvato Deshidrogenasa/análisis , Complejo Piruvato Deshidrogenasa/metabolismo , Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/enzimología , Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/genética , Tiamina/metabolismoRESUMEN
We developed a simple and sensitive stable-isotope dilution method for the quantification of 3-hydroxyglutaric acid (3HGA) and glutaric acid (GA) in body fluids. In our method, tert-butyldimethylsilyl (tBDMS) derivatives of 3HGA and GA were measured with a conventional electron-impact ionization (EI) mode in gas chromatography-mass spectrometry (GC-MS). The control values for 3HGA in nmol/ml were 0.15+/-0.08 (serum; n=10) and 0.07+/-0.03 (CSF; n=10). In addition, glutarylcarnitine and free carnitine were quantified by electrospray tandem mass spectrometry. Using these methods, we monitored 3HGA, GA, and glutarylcarnitine in the body fluids of three patients with glutaric aciduria type 1 found during newborn screening. None of the patients had experienced neurological strokes, which are possibly caused by the accumulation of 3HGA, at 15-24 months of age under a disease-specific treatment, including carnitine supplementation. Our data showed that 3HGA levels were relatively high in some serum samples with lower glutarylcarnitine and carnitine levels, suggesting that carnitine supplementation may play a role in preventing the accumulation of 3HGA in patients with this disease.
Asunto(s)
Errores Innatos del Metabolismo de los Aminoácidos/diagnóstico , Cromatografía de Gases y Espectrometría de Masas/métodos , Glutaratos/análisis , Tamizaje Neonatal/métodos , Errores Innatos del Metabolismo de los Aminoácidos/metabolismo , Deuterio/sangre , Deuterio/líquido cefalorraquídeo , Deuterio/orina , Glutaratos/metabolismo , Humanos , Recién Nacido , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
We studied six infants with thiamine-responsive congenital lactic acidosis and normal pyruvate dehydrogenase complex activity in vitro, through clinical and biochemical analysis. In addition to elevated lactate and pyruvate levels, the data revealed increased urinary excretion of alpha-ketoglutarate, alpha-ketoadipate, and branched chain ketoacids, indicating functional impairment of thiamine-requiring enzymes, such as pyruvate dehydrogenase complex, alpha-ketoglutarate dehydrogenase complex, alpha-ketoadipate dehydrogenase, and branched chain amino acid dehydrogenase. The metabolism of thiamine has not been investigated in patients with thiamine-responsive congenital lactic acidosis. We evaluated two specific transport systems, THTR-1 (SLC19A2) and THTR-2 (SLC19A3), and a pyrophosphorylating enzyme of thiamine, thiamine pyrophosphokinase (hTPK 1), in addition to pyruvate dehydrogenase complex and alpha-ketoglutarate dehydrogenase complex activity; no abnormality was found. Although the clinical features of thiamine-responsive congenital lactic acidosis are heterogeneous and clinical responses to thiamine administration vary, we emphasize the importance of early diagnosis and initiation of thiamine therapy before the occurrence of permanent brain damage. Careful monitoring of lactate and pyruvate would be useful in determining thiamine dosage.
Asunto(s)
Acidosis Láctica/tratamiento farmacológico , Acidosis Láctica/genética , Encéfalo/enzimología , Tiamina/administración & dosificación , Acidosis Láctica/congénito , Acidosis Láctica/metabolismo , Encéfalo/patología , Femenino , Genotipo , Humanos , Lactante , Recién Nacido , Complejo Cetoglutarato Deshidrogenasa/metabolismo , Imagen por Resonancia Magnética , Masculino , Proteínas de Transporte de Membrana/genética , Tiamina Pirofosfoquinasa/genética , Tiamina Pirofosfoquinasa/metabolismo , Tiamina/farmacocinéticaRESUMEN
To investigate the relationship between ghrelin and both fetal and neonatal growth parameters and energy balance, we measured plasma ghrelin concentrations in 54 cord blood samples (male, n = 34; female, n = 20; gestational age, 37.0-41.6 wk; birth weight, 2206-4326 g) and 47 neonatal blood samples (male, n = 27; female, n = 20; postnatal d 3-8). The plasma ghrelin concentrations in cord blood ranged from 110.6-446.1 pmol/liter (median, 206.7 pmol/liter), which were equal to or higher than those in normal weight adults. These values were inversely correlated with birth weight (r = -0.40; P = 0.002), birth length (r = -0.36; P = 0.007), placental weight (r = -0.35; P = 0.01), and IGF-I concentration (r = -0.49; P = 0.0002), but were not significantly correlated with the GH concentration (r = 0.22; P = 0.12). The ghrelin concentrations in small for gestational age newborn were significantly higher than those in appropriate for gestational age newborns (P = 0.0008). The ghrelin concentrations in the vein were significantly higher than those in the artery in 8 cord blood samples (P = 0.01), which suggests that the placenta is an important source of fetal ghrelin. In neonates, the ghrelin concentrations ranged from 133.0-481.7 pmol/liter (median, 268.3 pmol/liter), which were significantly higher than those in cord blood (P < 0.0001). These results suggest that ghrelin may contribute to fetal and neonatal growth.
Asunto(s)
Desarrollo Embrionario y Fetal/fisiología , Metabolismo Energético/fisiología , Sangre Fetal/metabolismo , Hormonas Peptídicas/sangre , Peso al Nacer , Femenino , Ghrelina , Humanos , Recién Nacido , Factor I del Crecimiento Similar a la Insulina/metabolismo , Masculino , RadioinmunoensayoRESUMEN
Pyruvate dehydrogenase complex (PDHC) deficiency is a major cause of congenital lactic acidemia in children. PDHC catalyzes the thiamine-dependent decarboxylation of pyruvate. Thiamine treatment was effective for some patients with PDHC deficiency. We reexamined 30 patients with congenital lactic acidemia of unknown origin who had normal PDHC activity in their cultured fibroblasts using a routine assay with a high (0.4 mM) thiamine pyrophosphate (TPP) concentration. We measured the activity of PDHC in the presence of a low (1x10(-4) mM) TPP concentration, and analyzed for mutations in the E1alpha subunit gene. Three males had low PDHC activity in the presence of 1x10(-4) mM TPP. The DNA sequence of these three patients' X-linked E1alpha subunit revealed a substitution of alanine for valine at position 71 (V71A) in exon 3, phenylalanine for cysteine at position 101 (C101F) in exon 4, and glycine for arginine at position 263 (R263G) in exon 8, respectively. Thiamine treatment was effective in these three patients. Therefore, they had a thiamine-responsive PDHC deficiency due to a point mutation in the E1alpha subunit gene. PDHC activity should be measured at a low TPP concentration to detect thiamine-responsive PDHC deficiency so that thiamine treatment can be initiated as soon as possible.
Asunto(s)
Piruvato Deshidrogenasa (Lipoamida)/genética , Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/diagnóstico , Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/genética , Tiamina/uso terapéutico , Acidosis Láctica/diagnóstico , Acidosis Láctica/tratamiento farmacológico , Acidosis Láctica/genética , Células Cultivadas , Niño , Preescolar , Análisis Mutacional de ADN , Fibroblastos/citología , Fibroblastos/enzimología , Humanos , Lactante , Masculino , Mutación Puntual , Piruvato Deshidrogenasa (Lipoamida)/metabolismo , Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/tratamiento farmacológico , Piel/citología , Piel/enzimologíaRESUMEN
Enlargement of the lateral ventricles and atrophy of the brain were documented ultrasonographically in utero at as early as 28th week of gestation in a female patient with lactic acidosis due to deficiency of the pyruvate dehydrogenase E1alpha subunit, demonstrating that the changes characteristic of this disease can occur antenatally. The mechanism of infantile spasms in this disease may be linked to mosaicism of the brain cells involving the normal enzyme and the mutant enzyme.
Asunto(s)
Enfermedades Fetales/patología , Diagnóstico Prenatal , Piruvato Deshidrogenasa (Lipoamida)/deficiencia , Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/complicaciones , Enfermedad por Deficiencia del Complejo Piruvato Deshidrogenasa/patología , Espasmos Infantiles/etiología , Electroencefalografía , Potenciales Evocados Auditivos , Femenino , Humanos , Lactante , Recién Nacido , Imagen por Resonancia Magnética , EmbarazoRESUMEN
Leigh syndrome, a severe neurodegenerative disorder, commonly is associated with cytochrome c oxidase deficiency. Recent studies in white patients indicate that SURF-1 gene mutations can cause Leigh syndrome associated with cytochrome c oxidase deficiency. When we measured cytochrome c oxidase activity in cultured lymphoblastoid cells from our Japanese patients with typical Leigh syndrome, three patients demonstrated cytochrome c oxidase deficiency. Three novel mutations of the SURF-1 gene were identified in two of these three patients with cytochrome c oxidase deficiency. All mutations predicted loss of function of the SURF-1 protein; in both patients' cells, cytochrome c oxidase activity was decreased to less than 20% of the control mean. These results indicate that cultured lymphoblastoid cells are useful for elucidating the etiology of Leigh syndrome, and that loss of function of the SURF-1 gene product can be responsible for Leigh syndrome associated with severe cytochrome c oxidase deficiency in Japanese patients.
Asunto(s)
Pueblo Asiatico/genética , Enfermedad de Leigh/genética , Mutación/genética , Proteínas/genética , Secuencia de Aminoácidos/genética , Secuencia de Bases/genética , Exones/genética , Femenino , Heterocigoto , Homocigoto , Humanos , Lactante , Japón , Masculino , Proteínas de la Membrana , Proteínas Mitocondriales , Reacción en Cadena de la Polimerasa , Polimorfismo Genético/genética , Polimorfismo de Longitud del Fragmento de RestricciónAsunto(s)
Ácido Dicloroacético/administración & dosificación , Ácido Dicloroacético/sangre , Enfermedad de Leigh/tratamiento farmacológico , Encéfalo/patología , Progresión de la Enfermedad , Humanos , Lactante , Enfermedad de Leigh/sangre , Imagen por Resonancia Magnética , Espectroscopía de Resonancia Magnética , Masculino , Monitoreo FisiológicoRESUMEN
A 1-year-old boy with methylmalonic acidemia had symmetrical lesions of the bilateral basal ganglia, which suggested Leigh encephalopathy. The findings on brain magnetic resonance imaging (MRI) and his physical condition greatly improved by the intravenous administration of vitamin B1. We hypothesized that in this case, clinical Leigh encephalopathy was caused by a impairment of the activity of pyruvate carboxylase induced by the accumulation of methylmalonyl CoA and an impairment of energy production due to a lack of vitamin B1, especially impairment of the activity of pyruvate dehydrogenase complex during an acute worsening of methylmalonic acidemia. Thus, in the treatment of methylmalonic acidemia, attention should be paid to vitamin B1 deficiency. During an acute worsening, vitamin B1 should be administered by intravenous drip injection.
Asunto(s)
Encéfalo/patología , Enfermedad de Leigh/diagnóstico , Ácido Metilmalónico/sangre , Humanos , Lactante , Enfermedad de Leigh/etiología , Imagen por Resonancia Magnética , Masculino , Metilmalonil-CoA Mutasa/metabolismo , Deficiencia de Tiamina/complicacionesAsunto(s)
Síndrome del Pelo Ensortijado/patología , Síndrome del Pelo Ensortijado/fisiopatología , Lóbulo Temporal/patología , Lóbulo Temporal/fisiopatología , Biomarcadores/metabolismo , Ceruloplasmina/deficiencia , Ceruloplasmina/metabolismo , Cobre/deficiencia , Cobre/metabolismo , Imagen de Difusión por Resonancia Magnética , Electroencefalografía , Complejo IV de Transporte de Electrones/metabolismo , Humanos , Lactante , Ácido Láctico/metabolismo , Angiografía por Resonancia Magnética , Imagen por Resonancia Magnética , Espectroscopía de Resonancia Magnética , Masculino , Síndrome del Pelo Ensortijado/diagnóstico , Síndrome del Pelo Ensortijado/enzimología , Ácido Pirúvico/metabolismoRESUMEN
Leigh syndrome (LS) is a progressive untreatable degenerating mitochondrial disorder caused by either mitochondrial or nuclear DNA mutations. A patient was a second child of unconsanguineous parents. On the third day of birth, he was transferred to neonatal intensive care units because of severe lactic acidosis. Since he was showing continuous lactic acidosis, the oral supplementation of dichloroacetate (DCA) was introduced on 31st day of birth at initial dose of 50 mg/kg, followed by maintenance dose of 25 mg/kg/every 12 h. The patient was diagnosed with LS due to a point mutation of an A-C at nucleotide 599 in exon 6 in the pyruvate dehydrogenase E1α gene, resulting in the substitution of aspartate for threonine at position 200 (N200T). Although the concentrations of lactate and pyruvate in blood were slightly decreased, his clinical conditions were deteriorating progressively. In order to overcome the mitochondrial or cytosolic energy crisis indicated by lactic acidosis as well as clinical symptoms, we terminated the DCA and administered 0.5 g/kg/day TID of sodium pyruvate orally. We analyzed the therapeutic effects of DCA or sodium pyruvate in the patient, and found that pyruvate therapy significantly decreased lactate, pyruvate and alanine levels, showed no adverse effects such as severe neuropathy seen in DCA, and had better clinical response on development and epilepsy. Though the efficacy of pyruvate on LS will be evaluated by randomized double-blind placebo-controlled study design in future, pyruvate therapy is a possible candidate for therapeutic choice for currently incurable mitochondrial disorders such as LS.
Asunto(s)
Ácido Dicloroacético/uso terapéutico , Enfermedad de Leigh/tratamiento farmacológico , Enfermedad de Leigh/genética , Mutación/genética , Piruvato Deshidrogenasa (Lipoamida)/genética , Ácido Pirúvico/uso terapéutico , Alanina/sangre , Células Cultivadas , Preescolar , Electroencefalografía , Fibroblastos/enzimología , Humanos , Ácido Láctico/sangre , Enfermedad de Leigh/fisiopatología , Masculino , Ácido Pirúvico/sangre , Ácido Pirúvico/líquido cefalorraquídeo , Estadísticas no ParamétricasRESUMEN
We report a 7-month-old boy with Menkes disease who presented West syndrome. Magnetic resonance imaging (MRI) revealed atrophy of the frontal and parietal lobes, subdural hematoma on the right side, and left temporal lobe lesion (low intensity in T1-weighted imaging (T1-WI), high intensity in T2-weighted imaging (T2-WI) and low intensity in diffusion-weighted imaging (DW-I)) at 7 months of age. The apparent diffusion coefficient (ADC) was 1.68×10(-3)mm(2)/s in the left temporal lobe lesion and 1.15×10(-3)mm(2)/s on the contralateral side. (1)H-magnetic resonance spectroscopy ((1)H-MRS) revealed a decrease in N-acetylaspartate/(creatine+phosphocreatine) (NAA/Cr) (0.71) and a lactate peak in the left temporal lobe lesion. At 8 months of age, the left temporal lobe lesion disappeared, the ADC of this lesion was within the normal range (1.10×10(-3)mm(2)/s), and (1)H-MRS revealed a slight increase in NAA/Cr (1.12) and disappearance of the lactate peak. We suspected that the transient temporal lobe lesion in Menkes disease was mainly vasogenic edema. Electroencephalography (EEG) revealed left hemisphere dominant hypsarrhythmia and slowing in the left hemisphere. Ictal EEG revealed generalized slow wave burst with P3, T3 spike antecedence and the antecedent spike was consistent with left temporal lobe lesion. After disappearance of the left temporal lobe lesion, tonic spasms disappeared and EEG findings improved. In this case, the clinical course and ictal EEG suggested that epileptic activity from the left temporal lobe lesion may have given rise to tonic spasms.